Vet Cold Chain Revolution Paves Way for Pet Stem Cell Therapies

SAN DIEGO, CA – February 27, 2026 – A landmark partnership announced today is set to overcome one of the biggest hurdles in advanced veterinary medicine, creating the infrastructure to deliver a new generation of stem cell therapies directly to clinics. Animal health biotechnology firm Gallant has teamed up with MWI Animal Health, a part of the global healthcare company Cencora, to establish the first-ever ultra-low temperature cold chain designed specifically for the veterinary market.

This strategic alliance is not just about logistics; it represents a foundational step toward making off-the-shelf regenerative medicine a practical reality for pets suffering from chronic and degenerative diseases. The new supply chain is being built in anticipation of Gallant’s lead product candidate, sonruvetcel, which is poised to become the first FDA-conditionally approved, off-the-shelf stem cell therapy for animals. By solving the complex challenge of distributing therapies that must be stored at a frigid -80°C (-112°F), the two companies are laying the groundwork for what they call a new category of veterinary care.

A New Frontier in Veterinary Logistics

The distribution of advanced biologic therapies requires precision and reliability far beyond that of typical pharmaceuticals. The partnership between Gallant and MWI Animal Health directly addresses this need by creating a specialized infrastructure modeled on the stringent standards of human medicine but tailored for the veterinary world.

Under the agreement, MWI will leverage its extensive supply chain expertise to develop and deploy a scalable, ultra-low temperature fulfillment model. This system will ensure that Gallant's therapies can be shipped overnight from MWI's central distribution center in Edwardsville, Kansas, to veterinary clinics across the continental United States, as well as Alaska, Hawaii, and Puerto Rico. This centralized model is key to maintaining the therapy's integrity from the manufacturing facility to the point of administration.

"Breakthrough science only matters if we can safely and reliably put it into the hands of veterinary professionals," said Dr. Linda Black, DVM, Ph.D., CEO of Gallant. "With MWI, we are pairing regenerative medicine innovation with world class supply chain management. This partnership helps ensure that, once approved, veterinarians can conveniently access an FDA-regulated, off-the-shelf stem cell therapy with confidence in its quality and integrity."

For MWI, this represents a significant investment in the future of animal health. "This partnership demonstrates how distribution innovation can unlock clinical innovation," stated Julia Loew, CCO at MWI Animal Health. "Stem cell therapies require precision handling. By investing in ultra-low temperature logistics tailored to veterinary practice, we are ensuring that this category of innovation can be delivered to clinics in the exact state intended, ready for safe and effective use."

Hope for Cats with a Painful Disease

The first therapy expected to utilize this new cold chain is sonruvetcel, an injectable suspension of mesenchymal stromal cells (MSCs) designed to treat refractory feline chronic gingivostomatitis (rFCGS). This severe and debilitating condition causes extreme, chronic inflammation of a cat’s gums and oral tissues, leading to intense pain, difficulty eating, and a severely diminished quality of life.

Current treatments for rFCGS often involve the extraction of all or most of a cat’s teeth, a drastic measure that still fails to provide relief for up to 30% of affected animals. For these refractory cases, options are limited to long-term immunosuppressants or pain medications, which can have significant side effects and offer only partial relief. This leaves a major unmet need for a safe and effective long-term solution.

Sonruvetcel, derived from donated uterine tissues, is an allogeneic or "off-the-shelf" therapy. This means it can be manufactured at scale, stored, and shipped for immediate use, bypassing the complex, time-consuming, and invasive process of harvesting stem cells from the patient itself. The therapy is believed to work by leveraging the natural immunomodulatory and regenerative properties of MSCs to reduce the excessive inflammation at the root of the disease and promote healing of the oral tissues.

Navigating the Path to Market

Gallant is pursuing conditional approval for sonruvetcel through the FDA's Center for Veterinary Medicine (CVM). This specific regulatory pathway is designed to make promising new animal drugs available sooner for serious or life-threatening conditions with unmet medical needs. Unlike an investigational drug used only in clinical trials, a conditionally approved product can be legally marketed and prescribed by veterinarians.

The conditional approval lasts for one year and can be renewed annually for up to four additional years. During this period, the manufacturer must continue to collect the comprehensive effectiveness data required for full FDA approval, while having already proven the product is safe and manufactured to consistent quality standards. This pathway provides earlier access for pets in need while ensuring rigorous oversight continues.

This regulatory strategy, combined with the logistical solution provided by MWI, is critical. A recent survey conducted by Gallant in collaboration with the American Animal Hospital Association (AAHA) found that 95% of veterinary professionals believe stem cell therapy will become a standard treatment option within the next decade. Crucially, 93% reported they would be more likely to offer such therapies if they were available in a convenient, off-the-shelf format delivered via a simple IV protocol—precisely the model Gallant is building.

This partnership is designed to serve as a blueprint for the future. The infrastructure being established is not just for a single product but is intended to support Gallant's broader pipeline of disease-modifying therapies for a range of inflammatory and degenerative conditions in companion animals, heralding a new and more accessible era of regenerative medicine for pets.